AU771437B2 - Methods for treating neurological injuries and disorders - Google Patents

Methods for treating neurological injuries and disorders Download PDF

Info

Publication number
AU771437B2
AU771437B2 AU53902/99A AU5390299A AU771437B2 AU 771437 B2 AU771437 B2 AU 771437B2 AU 53902/99 A AU53902/99 A AU 53902/99A AU 5390299 A AU5390299 A AU 5390299A AU 771437 B2 AU771437 B2 AU 771437B2
Authority
AU
Australia
Prior art keywords
gdf
fragment
derivative
mammal
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU53902/99A
Other languages
English (en)
Other versions
AU5390299A (en
Inventor
Ted Ebendal
Michael Jarpe
Mark Marchionni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scion Pharmaceuticals Inc
Original Assignee
Cenes Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cenes Pharmaceuticals Inc filed Critical Cenes Pharmaceuticals Inc
Publication of AU5390299A publication Critical patent/AU5390299A/en
Assigned to CENES PHARMACEUTICALS, INC. reassignment CENES PHARMACEUTICALS, INC. Amend patent request/document other than specification (104) Assignors: CAMBRIDGE NEUROSCIENCE, INC.
Application granted granted Critical
Publication of AU771437B2 publication Critical patent/AU771437B2/en
Assigned to SCION PHARMACEUTICALS, INC. reassignment SCION PHARMACEUTICALS, INC. Alteration of Name(s) in Register under S187 Assignors: CENES PHARMACEUTICALS, INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU53902/99A 1998-07-06 1999-07-02 Methods for treating neurological injuries and disorders Ceased AU771437B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9179198P 1998-07-06 1998-07-06
US60/091791 1998-07-06
PCT/US1999/015106 WO2000001440A2 (fr) 1998-07-06 1999-07-02 Procedes de traitement de blessures et de troubles neurologiques

Publications (2)

Publication Number Publication Date
AU5390299A AU5390299A (en) 2000-01-24
AU771437B2 true AU771437B2 (en) 2004-03-25

Family

ID=22229675

Family Applications (1)

Application Number Title Priority Date Filing Date
AU53902/99A Ceased AU771437B2 (en) 1998-07-06 1999-07-02 Methods for treating neurological injuries and disorders

Country Status (6)

Country Link
EP (1) EP1094863A4 (fr)
JP (1) JP2002519394A (fr)
KR (1) KR20010079503A (fr)
AU (1) AU771437B2 (fr)
CA (1) CA2336718A1 (fr)
WO (1) WO2000001440A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1439191E (pt) * 2004-01-19 2006-06-30 Ares Trading Sa Processo para a purificacao de proteinas expressas de forma bacteriana
JPWO2008133141A1 (ja) * 2007-04-24 2010-07-22 東洋紡績株式会社 オスモチン組換えタンパク質およびその製造方法、並びにその利用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635372A (en) * 1995-05-18 1997-06-03 Genetics Institute, Inc. BMP-15 compositions
US5652118A (en) * 1991-03-11 1997-07-29 Creative Biomolecules, Inc. Nucleic acid encoding a novel morphogenic protein, OP-3
US5767252A (en) * 1996-04-08 1998-06-16 The Johns Hopkins University School Of Medicine Neuronal cell growth factor, Narp

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE184052T1 (de) * 1990-06-15 1999-09-15 Carnegie Inst Of Washington Gdf-1 und uog1 proteine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652118A (en) * 1991-03-11 1997-07-29 Creative Biomolecules, Inc. Nucleic acid encoding a novel morphogenic protein, OP-3
US5635372A (en) * 1995-05-18 1997-06-03 Genetics Institute, Inc. BMP-15 compositions
US5767252A (en) * 1996-04-08 1998-06-16 The Johns Hopkins University School Of Medicine Neuronal cell growth factor, Narp

Also Published As

Publication number Publication date
WO2000001440A2 (fr) 2000-01-13
EP1094863A2 (fr) 2001-05-02
AU5390299A (en) 2000-01-24
CA2336718A1 (fr) 2000-01-13
JP2002519394A (ja) 2002-07-02
EP1094863A4 (fr) 2005-02-02
KR20010079503A (ko) 2001-08-22
WO2000001440A3 (fr) 2000-04-20

Similar Documents

Publication Publication Date Title
AU745324B2 (en) Therapeutic methods comprising use of a neuregulin
US20060241046A1 (en) Linear gamma-carboxyglutamate rich conotoxins
DE60223511T2 (de) Neurotrophe faktoren
JP4153036B2 (ja) 截形グリア細胞系由来神経栄養因子
SK65998A3 (en) Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (gdnf) protein product
HU220795B1 (hu) Gliasejtvonal-eredetű neurotróf faktorfehérjék, továbbá berendezések és gyógyászati készítmények idegsejtkárosodás megelőzésére és kezelésére
CZ149998A3 (cs) Použití proteinového produktu neurotrofického faktoru (GDNF) odvozeného od gliální buněčné linie pro výrobu farmaceutické kompozice
US6486122B1 (en) Methods of increasing body weight in a subject by administering TGF-α
US6872698B2 (en) Methods for treating neurological injuries and disorders
AU771437B2 (en) Methods for treating neurological injuries and disorders
EP3777878A1 (fr) Compositions et procede de traitement pendant des periodes non aiguës a la suite de lesion neurologique snc
CN109106943B (zh) 抗癫痫的毒素Martentoxin及其应用
WO1997005893A1 (fr) Remede contre les troubles ophtalmiques
EP1897441A1 (fr) Fragments fonctionnels de TGF-alpha polypeptides et leurs procédés d'utilisation
WO1997003689A1 (fr) Procede de traitement de l'epilepsie au moyen du facteur neurotrophique derive du cerveau
US20060172948A1 (en) Gamma-carboxyglutamate containing conopeptides
US20020128193A1 (en) Retro-inverso prosaposin-derived peptides and use thereof

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: CENES PHARMACEUTICALS, INC.

Free format text: FORMER NAME: CAMBRIDGE NEUROSCIENCE, INC.

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: SCION PHARMACEUTICALS, INC.

Free format text: FORMER OWNER WAS: CENES PHARMACEUTICALS, INC.